Liquid Biopsy Market by Product & Service (Kits, Instruments), Circulating Biomarker (ctDNA, cfDNA, CTC), Technology (NGS, PCR), Application (Lung, Breast, Prostate Cancer), Sample Type (Blood, Urine, CSF), End User (Hospitals) - Global Forecast to 2030

1 INTRODUCTION 35 1.1 STUDY OBJECTIVES 35 1.2 MARKET DEFINITION 35 1.3 MARKET SCOPE 36 1.3.1 MARKETS COVERED & REGIONAL SCOPE 36 1.3.2 INCLUSIONS & EXCLUSIONS 37 1.3.3 YEARS CONSIDERED 38 1.3.4 CURRENCY CONSIDERED 38 1.4 KEY STAKEHOLDERS 38 1.5 SUMMARY OF CHANGES 39 2 RESEARCH METHODOLOGY 40 2.1 RESEARCH DATA 40 2.2 RESEARCH APPROACH 40 2.2.1 SECONDARY DATA 41 2.2.1.1 Key secondary sources 41 2.2.1.2 Key data from secondary sources 41 2.2.2 PRIMARY DATA 42 2.2.2.1 Primary sources 43 2.2.2.2 Key data from primary sources 43 2.2.2.3 Key industry insights 45 2.2.2.4 Breakdown of primary interviews 45 2.3 MARKET SIZE ESTIMATION 46 2.3.1 BOTTOM-UP APPROACH 47 2.3.1.1 Approach 1: Company revenue estimation approach 47 2.3.1.2 Approach 2: Presentations of companies and primary interviews 47 2.3.1.3 Growth forecast 48 2.3.1.4 CAGR projections 48 2.3.2 TOP-DOWN APPROACH 48 2.4 MARKET BREAKDOWN & DATA TRIANGULATION 50 2.5 MARKET SHARE ASSESSMENT 50 2.6 RESEARCH ASSUMPTIONS 51 2.6.1 PARAMETRIC ASSUMPTIONS 51 2.7 RESEARCH LIMITATIONS 51 2.8 RISK ASSESSMENT 52 3 EXECUTIVE SUMMARY 53   4 PREMIUM INSIGHTS 59 4.1 LIQUID BIOPSY MARKET OVERVIEW 59 4.2 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION) 60 4.3 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2025 VS. 2030 (USD MILLION) 60 4.4 LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION) 61 4.5 LIQUID BIOPSY MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 61 4.6 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2025 VS. 2030 (USD MILLION) 62 4.7 LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2025 VS. 2030 (USD MILLION) 62 4.8 LIQUID BIOPSY MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 63 4.9 LIQUID BIOPSY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 63 5 MARKET OVERVIEW 64 5.1 INTRODUCTION 64 5.2 MARKET DYNAMICS 64 5.2.1 DRIVERS 65 5.2.1.1 Increasing burden of cancer 65 5.2.1.2 Cancer awareness initiatives undertaken by global health organizations 66 5.2.1.3 Expanding benefits of liquid biopsy over traditional biopsy procedures 67 5.2.2 RESTRAINTS 68 5.2.2.1 Lower sensitivity of specific liquid biopsy procedures 68 5.2.3 OPPORTUNITIES 69 5.2.3.1 Growing significance of companion diagnostics 69 5.2.3.2 Growth potential of emerging economies 69 5.2.4 CHALLENGES 70 5.2.4.1 Unfavorable reimbursement scenario 70 5.3 PRICING ANALYSIS 70 5.3.1 INDICATIVE SELLING PRICE TREND OF LIQUID BIOPSY PRODUCTS, 2023−2025 71 5.3.2 INDICATIVE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER, 2023−2025 71 5.3.3 INDICATIVE SELLING PRICE TREND OF LIQUID BIOPSY PRODUCTS, BY REGION, 2023−2025 72 5.4 PATENT ANALYSIS 73 5.4.1 LIST OF MAJOR PATENTS 74 5.5 VALUE CHAIN ANALYSIS 75 5.6 SUPPLY CHAIN ANALYSIS 77 5.7 TRADE ANALYSIS 78 5.7.1 TRADE ANALYSIS FOR DIAGNOSTIC & LABORATORY REAGENTS 78 5.7.2 IMPORT DATA (HS CODE 3822) 78 5.7.3 EXPORT DATA (HS CODE 3822) 79 5.8 ECOSYSTEM ANALYSIS 79 5.9 PORTER’S FIVE FORCES ANALYSIS 81 5.9.1 THREAT OF NEW ENTRANTS 82 5.9.2 THREAT OF SUBSTITUTES 82 5.9.3 BARGAINING POWER OF BUYERS 82 5.9.4 BARGAINING POWER OF SUPPLIERS 82 5.9.5 INTENSITY OF COMPETITIVE RIVALRY 82 5.10 REGULATORY LANDSCAPE 83 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83 5.10.2 NORTH AMERICA 84 5.10.2.1 US 84 5.10.2.2 Canada 85 5.10.3 EUROPE 85 5.10.4 ASIA PACIFIC 86 5.10.4.1 China 86 5.10.4.2 Japan 86 5.10.4.3 India 86 5.10.5 LATIN AMERICA 87 5.10.5.1 Brazil 87 5.10.5.2 Mexico 87 5.10.6 MIDDLE EAST 87 5.10.6.1 Africa 88 5.11 TECHNOLOGY ANALYSIS 88 5.11.1 KEY TECHNOLOGIES 88 5.11.1.1 Digital Droplet PCR (ddPCR) 88 5.11.1.2 Tagged-amplicon Deep Sequencing (TAm-Seq) 88 5.11.2 COMPLEMENTARY TECHNOLOGIES 88 5.11.2.1 Electrochemical biosensing technology 88 5.11.3 ADJACENT TECHNOLOGIES 89 5.11.3.1 Microfluidic-based devices 89 5.12 KEY CONFERENCES & EVENTS, 2025–2026 89 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 90 5.14 KEY STAKEHOLDERS & BUYING CRITERIA 91 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 92 5.14.2 BUYING CRITERIA 92 5.15 INVESTMENT & FUNDING SCENARIO 93 5.16 CASE STUDY ANALYSIS 94 5.16.1 CASE STUDY 1: DETECTION OF LOW-FREQUENCY MUTATIONS USING TARGET SELECTOR CTDNA TECHNOLOGY 94 5.16.2 CASE STUDY 2: ANALYTICAL ASSESSMENT OF PLASMA & SERUM FOR CTDNA MUTATION DETECTION 94   5.17 IMPACT OF AI/GENERATIVE AI ON LIQUID BIOPSY MARKET 95 5.17.1 INTRODUCTION 95 5.17.2 MARKET POTENTIAL OF AI 95 5.17.3 AI USE CASES 96 5.17.4 FUTURE OF AI IN LIQUID BIOPSY MARKET 97 5.18 TRUMP TARIFF IMPACT ON LIQUID BIOPSY MARKET 97 5.18.1 INTRODUCTION 97 5.18.2 KEY TARIFF RATES 97 5.18.3 PRICE IMPACT ANALYSIS 98 5.18.4 KEY IMPACT ON COUNTRY/REGION 98 5.18.4.1 North America 98 5.18.4.2 Europe 99 5.18.4.3 Asia Pacific 99 5.18.5 IMPACT ON END-USE INDUSTRIES 99 5.18.5.1 Reference laboratories 99 5.18.5.2 Hospitals & physicians’ laboratories 99 5.18.5.3 Academic & research centers 99 6 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE 100 6.1 INTRODUCTION 101 6.2 ASSAY KITS 101 6.2.1 RECURRING PURCHASE TO PROPEL MARKET 101 6.3 INSTRUMENTS 105 6.3.1 RISING TECHNOLOGICAL ADVANCES IN DDPCR TO FUEL MARKET 105 6.4 SERVICES 108 6.4.1 ADOPTION OF CFDNA & CTC TESTING SERVICES TO SUPPORT MARKET GROWTH 108 7 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE 111 7.1 INTRODUCTION 112 7.2 CIRCULATING TUMOR DNA 112 7.2.1 HIGH SENSITIVITY & SPECIFICITY TO PROPEL MARKET 112 7.3 CELL-FREE DNA 116 7.3.1 BROADENING APPLICATIONS IN PRENATAL SCREENING TO DRIVE MARKET 116 7.4 CIRCULATING TUMOR CELLS 119 7.4.1 EASY COLLECTION AND PERSISTENT ASSESSMENT & ANALYSIS OF TUMORS TO FUEL MARKET 119 7.5 EXTRACELLULAR VESICLES 122 7.5.1 HIGH STABILITY IN BLOOD CIRCULATION TO ENSURE CONSISTENT GROWTH 122 7.6 OTHER CIRCULATING BIOMARKERS 124   8 LIQUID BIOPSY MARKET, BY TECHNOLOGY 128 8.1 INTRODUCTION 129 8.2 MULTI-GENE PARALLEL ANALYSIS USING NGS 129 8.2.1 HIGHER THROUGHPUT EFFICIENCY TO PROPEL MARKET 129 8.3 SINGLE-GENE ANALYSIS USING PCR MICROARRAYS 132 8.3.1 COST-EFFICIENCY AND EASE OF USE TO FUEL UPTAKE 132 9 LIQUID BIOPSY MARKET, BY APPLICATION 136 9.1 INTRODUCTION 137 9.2 CANCER APPLICATIONS 137 9.2.1 LUNG CANCER 141 9.2.1.1 Growing prevalence of lung cancer to propel market 141 9.2.2 BREAST CANCER 144 9.2.2.1 Increasing funding investments for breast cancer research to drive market 144 9.2.3 COLORECTAL CANCER 148 9.2.3.1 Rising geriatric population to fuel uptake 148 9.2.4 PROSTATE CANCER 151 9.2.4.1 Adoption of tumor cell kits to boost demand 151 9.2.5 MELANOMA 154 9.2.5.1 Growing need for early diagnosis of genetically mutated tumors to drive market 154 9.2.6 OTHER CANCERS 157 9.3 NON-CANCER APPLICATIONS 160 9.3.1 NON-INVASIVE PRENATAL TESTING 163 9.3.1.1 Growing demand for NIPT in high-risk pregnancies to drive market 163 9.3.2 ORGAN TRANSPLANTATION 166 9.3.2.1 Early disease diagnosis & detection to support market growth 166 9.3.3 INFECTIOUS DISEASE TESTING 168 9.3.3.1 Potential accuracy & efficacy for testing to fuel uptake 168 10 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION 171 10.1 INTRODUCTION 172 10.2 THERAPY SELECTION 172 10.2.1 GROWING PREFERENCE FOR PERSONALIZED TREATMENT TO DRIVE MARKET 172 10.3 TREATMENT MONITORING 175 10.3.1 EARLY DETECTION OF DISEASE PROGRESSION TO BOOST DEMAND 175 10.4 EARLY CANCER SCREENING 177 10.4.1 GROWING INCIDENCE OF CANCER AND RISING FUNDING INVESTMENTS TO PROPEL MARKET 177   10.5 RECURRENCE MONITORING 180 10.5.1 RISING NEED FOR POST-TREATMENT SURVEILLANCE TO FUEL UPTAKE 180 11 LIQUID BIOPSY MARKET, BY SAMPLE TYPE 183 11.1 INTRODUCTION 184 11.2 BLOOD SAMPLES 185 11.2.1 STANDARD SIMPLICITY AND HIGH PATIENT ACCEPTANCE TO PROPEL MARKET 185 11.3 OTHER SAMPLE TYPES 188 12 LIQUID BIOPSY MARKET, BY END USER 191 12.1 INTRODUCTION 192 12.2 REFERENCE LABORATORIES 192 12.2.1 RISING OUTSOURCING OF TESTS AND ABILITY TO UNDERTAKE LARGE SAMPLE VOLUMES TO PROPEL MARKET 192 12.3 HOSPITALS & PHYSICIANS LABORATORIES 195 12.3.1 INCREASING ESTABLISHMENT OF HOSPITALS TO BOOST DEMAND 195 12.4 ACADEMIC & RESEARCH CENTERS 198 12.4.1 INCREASING R&D ACTIVITIES FOR INNOVATIVE TESTS TO SUPPORT MARKET GROWTH 198 12.5 OTHER END USERS 201 13 LIQUID BIOPSY MARKET, BY REGION 204 13.1 INTRODUCTION 205 13.2 NORTH AMERICA 205 13.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 206 13.2.2 US 211 13.2.2.1 High healthcare expenditure to propel market 211 13.2.3 CANADA 215 13.2.3.1 Availability of various cancer screening programs to drive market 215 13.3 EUROPE 220 13.3.1 EUROPE: MACROECONOMIC OUTLOOK 220 13.3.2 GERMANY 225 13.3.2.1 Favorable research funding investments for cancer research to fuel market 225 13.3.3 UK 229 13.3.3.1 NHS-funded lab-based disease screening facilities to boost demand 229 13.3.4 FRANCE 233 13.3.4.1 Growing focus on expanding access to advanced genomic technologies to drive market 233 13.3.5 ITALY 237 13.3.5.1 Development of novel circulating cancer biomarkers to support market growth 237 13.3.6 SPAIN 241 13.3.6.1 Focus on personalized medicine to support market uptake 241 13.3.7 REST OF EUROPE 245 13.4 ASIA PACIFIC 249 13.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 249 13.4.2 CHINA 254 13.4.2.1 Increasing incidence of infectious diseases to propel market 254 13.4.3 JAPAN 258 13.4.3.1 Universal healthcare reimbursement policy to fuel market 258 13.4.4 INDIA 262 13.4.4.1 Increasing incidence of chronic diseases and growing focus on early disease diagnosis to drive market 262 13.4.5 REST OF ASIA PACIFIC 266 13.5 LATIN AMERICA 270 13.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK 271 13.5.2 BRAZIL 275 13.5.2.1 Improvements in laboratory infrastructure to drive market 275 13.5.3 MEXICO 279 13.5.3.1 Improving accessibility to advanced healthcare services to support market growth 279 13.5.4 REST OF LATIN AMERICA 283 13.6 MIDDLE EAST & AFRICA 287 13.6.1 INCREASING COLLABORATIONS & DEVELOPMENTS FOR ENHANCED DIAGNOSTIC ACCESS TO SUPPORT MARKET GROWTH 287 13.6.2 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 287 14 COMPETITIVE LANDSCAPE 292 14.1 INTRODUCTION 292 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 292 14.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN LIQUID BIOPSY MARKET 292 14.3 REVENUE ANALYSIS, 2022−2024 294 14.4 MARKET SHARE ANALYSIS 295 14.4.1 LIQUID BIOPSY MARKET 295 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS 297 14.5.1 STARS 297 14.5.2 EMERGING LEADERS 297 14.5.3 PERVASIVE PLAYERS 297 14.5.4 PARTICIPANTS 297 14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 299 14.5.5.1 Company footprint 299 14.5.5.2 Region footprint 300 14.5.5.3 Product & Service footprint 300   14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES 301 14.6.1 PROGRESSIVE COMPANIES 301 14.6.2 RESPONSIVE COMPANIES 301 14.6.3 DYNAMIC COMPANIES 301 14.6.4 STARTING BLOCKS 302 14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 303 14.6.5.1 Detailed list of key startups/SMEs 303 14.6.5.2 Competitive benchmarking of key startups/SMEs, by product & service 303 14.6.5.3 Competitive benchmarking of key startups/SMEs, by region 304 14.7 COMPANY VALUATION & FINANCIAL METRICS 305 14.7.1 FINANCIAL METRICS 305 14.7.2 COMPANY VALUATION 305 14.8 BRAND/PRODUCT COMPARATIVE ANALYSIS 306 14.8.1 BRAND COMPARISON OF PCR-BASED LIQUID BIOPSY ASSAYS 306 14.8.1.1 QIAGEN N.V. 306 14.8.1.2 Thermo Fisher Scientific Inc. 307 14.8.1.3 Bio-Rad Laboratories, Inc. 307 14.9 COMPETITIVE SCENARIO 307 14.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS 307 14.9.2 DEALS 308 14.9.3 EXPANSIONS 309 15 COMPANY PROFILES 311 15.1 KEY PLAYERS 311 15.1.1 NATERA, INC. 311 15.1.1.1 Business overview 311 15.1.1.2 Products/Services offered 312 15.1.1.3 Recent developments 313 15.1.1.3.1 Product/Service launches 313 15.1.1.3.2 Deals 314 15.1.1.3.3 Other developments 314 15.1.1.4 MnM view 314 15.1.1.4.1 Key strengths 314 15.1.1.4.2 Strategic choices 314 15.1.1.4.3 Weaknesses & competitive threats 315 15.1.2 GUARDANT HEALTH 316 15.1.2.1 Business overview 316 15.1.2.2 Products/Services offered 317 15.1.2.3 Recent developments 318 15.1.2.3.1 Product/Service launches & approvals 318 15.1.2.3.2 Deals 320 15.1.2.4 MnM view 322 15.1.2.4.1 Key strengths 322 15.1.2.4.2 Strategic choices 322 15.1.2.4.3 Weaknesses & competitive threats 322 15.1.3 MYRIAD GENETICS, INC. 323 15.1.3.1 Business overview 323 15.1.3.2 Products/Services offered 324 15.1.3.3 Recent developments 325 15.1.3.3.1 Product/Service launches 325 15.1.3.3.2 Deals 325 15.1.3.4 MnM view 328 15.1.3.4.1 Key strengths 328 15.1.3.4.2 Strategic choices 328 15.1.3.4.3 Weaknesses & competitive threats 328 15.1.4 ILLUMINA, INC. 329 15.1.4.1 Business overview 329 15.1.4.2 Products/Services offered 330 15.1.4.3 Recent developments 331 15.1.4.3.1 Product/Service launches & approvals 331 15.1.4.3.2 Deals 332 15.1.4.3.3 Expansions 333 15.1.4.3.4 Other developments 334 15.1.4.4 MnM view 334 15.1.4.4.1 Key strengths 334 15.1.4.4.2 Strategic choices 334 15.1.4.4.3 Weaknesses & competitive threats 334 15.1.5 F. HOFFMANN-LA ROCHE LTD. 335 15.1.5.1 Business overview 335 15.1.5.2 Products/Services offered 336 15.1.5.3 Recent developments 337 15.1.5.3.1 Product/Service launches 337 15.1.5.3.2 Expansions 338 15.1.5.4 MnM view 338 15.1.5.4.1 Key strengths 338 15.1.5.4.2 Strategic choices 338 15.1.5.4.3 Weaknesses & competitive threats 338 15.1.6 QIAGEN N.V. 339 15.1.6.1 Business overview 339 15.1.6.2 Products/Services offered 340 15.1.6.3 Recent developments 341 15.1.6.3.1 Product/Service launches 341 15.1.6.3.2 Deals 342 15.1.6.3.3 Expansions 344 15.1.7 EXACT SCIENCES CORPORATION 345 15.1.7.1 Business overview 345 15.1.7.2 Products/Services offered 346 15.1.7.3 Recent developments 347 15.1.7.3.1 Product/Service launches 347 15.1.7.3.2 Deals 347 15.1.8 THERMO FISHER SCIENTIFIC INC. 349 15.1.8.1 Business overview 349 15.1.8.2 Products/Services offered 350 15.1.8.3 Recent developments 351 15.1.8.3.1 Product/Service launches 351 15.1.8.3.2 Deals 352 15.1.8.3.3 Expansions 353 15.1.9 GRAIL, INC. 354 15.1.9.1 Business overview 354 15.1.9.2 Products/Services offered 355 15.1.9.3 Recent developments 355 15.1.9.3.1 Product/Service approvals 355 15.1.9.3.2 Deals 355 15.1.10 BIO-RAD LABORATORIES, INC. 357 15.1.10.1 Business overview 357 15.1.10.2 Products/Services offered 359 15.1.10.3 Recent developments 359 15.1.10.3.1 Product/Service launches 359 15.1.10.3.2 Deals 360 15.1.11 SYSMEX CORPORATION 361 15.1.11.1 Business overview 361 15.1.11.2 Products/Services offered 362 15.1.11.3 Recent developments 363 15.1.11.3.1 Deals 363 15.1.11.3.2 Expansions 364 15.1.12 MDXHEALTH 365 15.1.12.1 Business overview 365 15.1.12.2 Products/Services offered 366 15.1.12.3 Recent developments 366 15.1.12.3.1 Deals 366 15.1.13 PERSONALIS, INC. 367 15.1.13.1 Business overview 367 15.1.13.2 Products/Services offered 368 15.1.13.3 Recent developments 369 15.1.13.3.1 Product/Service launches 369 15.1.13.3.2 Deals 369 15.1.14 THE MENARINI GROUP 371 15.1.14.1 Business overview 371 15.1.14.2 Products/Services offered 371 15.1.14.3 Recent developments 372 15.1.14.3.1 Product/Service launches 372 15.1.14.3.2 Deals 372 15.2 OTHER PLAYERS 373 15.2.1 NEOGENOMICS LABORATORIES 373 15.2.2 ANGLE PLC 374 15.2.3 LABCORP HOLDINGS INC. 375 15.2.4 BIO-TECHNE 376 15.2.5 MESA LABS, INC. 377 15.2.6 MEDGENOME 378 15.2.7 LUNGLIFE AI, INC. 379 15.2.8 STRAND 380 15.2.9 VORTEX BIOTECH HOLDINGS 381 15.2.10 FREENOME HOLDINGS, INC. 381 15.2.11 LUCENCE HEALTH INC. 382 15.2.12 NEW DAY DIAGNOSTICS, LLC 383 16 APPENDIX 384 16.1 DISCUSSION GUIDE 384 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 389 16.3 CUSTOMIZATION OPTIONS 391 16.4 RELATED REPORTS 391 16.5 AUTHOR DETAILS 392

TABLE 1 LIQUID BIOPSY MARKET: KEY DATA FROM PRIMARY SOURCES 43 TABLE 2 LIQUID BIOPSY MARKET: RISK ASSESSMENT ANALYSIS 52 TABLE 3 INCIDENCE OF CANCER CASES WORLDWIDE, BY TYPE (2022) 66 TABLE 4 PROJECTED INCREASE IN CANCER PATIENTS, 2022 VS. 2035 VS. 2050, BY REGION 66 TABLE 5 INDICATIVE SELLING PRICING TREND OF LIQUID BIOPSY PRODUCTS, 2023–2025 71 TABLE 6 INDICATIVE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER, 2023–2025 71 TABLE 7 INDICATIVE SELLING PRICE TREND OF LIQUID BIOPSY PRODUCTS, BY REGION, 2023–2025 72 TABLE 8 LIQUID BIOPSY MARKET: LIST OF KEY PATENTS 74 TABLE 9 IMPORT DATA (HS CODE 3822), BY COUNTRY, 2020–2024 (USD MILLION) 78 TABLE 10 EXPORT DATA (HS CODE 3822), BY COUNTRY, 2020–2024 (USD MILLION) 79 TABLE 11 LIQUID BIOPSY MARKET: ROLE IN THE ECOSYSTEM 80 TABLE 12 LIQUID BIOPSY MARKET: PORTER’S FIVE FORCES ANALYSIS 81 TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83 TABLE 18 EUROPE: CLASSIFICATION OF DEVICES 85 TABLE 19 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 86 TABLE 20 LIQUID BIOPSY MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026 89 TABLE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LIQUID BIOPSY PRODUCTS (%) 92 TABLE 22 KEY BUYING CRITERIA FOR LIQUID BIOPSY PRODUCTS, BY RANK 93 TABLE 23 IMPLEMENTATION OF AI, BY KEY COMPANY & USE CASE 96 TABLE 24 US-ADJUSTED RECIPROCAL TARIFF RATES 97 TABLE 25 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 101 TABLE 26 KEY ASSAY KITS CURRENTLY OFFERED 102 TABLE 27 LIQUID BIOPSY ASSAY KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 103 TABLE 28 NORTH AMERICA: LIQUID BIOPSY ASSAY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 104 TABLE 29 EUROPE: LIQUID BIOPSY ASSAY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 104 TABLE 30 ASIA PACIFIC: LIQUID BIOPSY ASSAY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 104 TABLE 31 LATIN AMERICA: LIQUID BIOPSY ASSAY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 105 TABLE 32 KEY INSTRUMENTS CURRENTLY OFFERED 106 TABLE 33 LIQUID BIOPSY INSTRUMENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 106 TABLE 34 NORTH AMERICA: LIQUID BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 107 TABLE 35 EUROPE: LIQUID BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 107 TABLE 36 ASIA PACIFIC: LIQUID BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 107 TABLE 37 LATIN AMERICA: LIQUID BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 108 TABLE 38 LIQUID BIOPSY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 109 TABLE 39 NORTH AMERICA: LIQUID BIOPSY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 109 TABLE 40 EUROPE: LIQUID BIOPSY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 109 TABLE 41 ASIA PACIFIC: LIQUID BIOPSY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 110 TABLE 42 LATIN AMERICA: LIQUID BIOPSY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 110 TABLE 43 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION) 112 TABLE 44 KEY CTDNA PRODUCTS CURRENTLY AVAILABLE 113 TABLE 45 LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY REGION, 2023–2030 (USD MILLION) 114 TABLE 46 NORTH AMERICA: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY COUNTRY, 2023–2030 (USD MILLION) 114 TABLE 47 EUROPE: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 48 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 49 LATIN AMERICA: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 50 KEY CELL-FREE DNA PRODUCTS CURRENTLY AVAILABLE 116 TABLE 51 LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY REGION, 2023–2030 (USD MILLION) 117 TABLE 52 NORTH AMERICA: LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 53 EUROPE: LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY COUNTRY, 2023–2030 (USD MILLION) 118 TABLE 54 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY COUNTRY, 2023–2030 (USD MILLION) 118 TABLE 55 LATIN AMERICA: LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 56 KEY CTC PRODUCTS CURRENTLY AVAILABLE 120 TABLE 57 LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY REGION, 2023–2030 (USD MILLION) 120 TABLE 58 NORTH AMERICA: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 59 EUROPE: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 60 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 61 LATIN AMERICA: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 62 KEY EXTRACELLULAR VESICLE PRODUCTS CURRENTLY AVAILABLE 122 TABLE 63 LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY REGION, 2023–2030 (USD MILLION) 122 TABLE 64 NORTH AMERICA: LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 65 EUROPE: LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 66 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 67 LATIN AMERICA: LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY COUNTRY, 2023–2030 (USD MILLION) 124 TABLE 68 OTHER CIRCULATING BIOMARKER PRODUCTS CURRENTLY AVAILABLE 124 TABLE 69 LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY REGION, 2023–2030 (USD MILLION) 125 TABLE 70 NORTH AMERICA: LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 71 EUROPE: LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 72 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 73 LATIN AMERICA: LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 74 LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 129 TABLE 75 KEY NGS-BASED PRODUCTS CURRENTLY AVAILABLE 130 TABLE 76 LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY REGION, 2023–2030 (USD MILLION) 130 TABLE 77 NORTH AMERICA: LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 78 EUROPE: LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 79 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 80 LATIN AMERICA: LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 81 KEY PCR & MICROARRAY-BASED PRODUCTS CURRENTLY AVAILABLE 133 TABLE 82 LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY REGION, 2023–2030 (USD MILLION) 133 TABLE 83 NORTH AMERICA: LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 84 EUROPE: LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 85 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 86 LATIN AMERICA: LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 87 LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 137 TABLE 88 GLOBAL CANCER INCIDENCE, 2022 VS. 2035 VS. 2045, BY REGION 138 TABLE 89 LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 139 TABLE 90 NORTH AMERICA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 139 TABLE 91 EUROPE: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 92 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 93 LATIN AMERICA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 94 LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 141 TABLE 95 GLOBAL LUNG CANCER INCIDENCE, 2022 VS. 2035 VS. 2050 142 TABLE 96 KEY LIQUID BIOPSY PRODUCTS FOR LUNG CANCER 142 TABLE 97 LIQUID BIOPSY MARKET FOR LUNG CANCER, BY REGION, 2023–2030 (USD MILLION) 143 TABLE 98 NORTH AMERICA: LIQUID BIOPSY MARKET FOR LUNG CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 99 EUROPE: LIQUID BIOPSY MARKET FOR LUNG CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 100 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR LUNG CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 101 LATIN AMERICA: LIQUID BIOPSY MARKET FOR LUNG CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 102 GLOBAL BREAST CANCER INCIDENCE, 2022 VS. 2035 VS. 2050 145 TABLE 103 KEY LIQUID BIOPSY PRODUCTS FOR BREAST CANCER 146 TABLE 104 LIQUID BIOPSY MARKET FOR BREAST CANCER, BY REGION, 2023–2030 (USD MILLION) 146 TABLE 105 NORTH AMERICA: LIQUID BIOPSY MARKET FOR BREAST CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 106 EUROPE: LIQUID BIOPSY MARKET FOR BREAST CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 107 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR BREAST CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 108 LATIN AMERICA: LIQUID BIOPSY MARKET FOR BREAST CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 109 GLOBAL COLORECTAL CANCER INCIDENCE, 2022 VS. 2035 VS. 2050 149 TABLE 110 KEY LIQUID BIOPSY PRODUCTS FOR COLORECTAL CANCER 149 TABLE 111 LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY REGION, 2023–2030 (USD MILLION) 149 TABLE 112 NORTH AMERICA: LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 113 EUROPE: LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 114 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 115 LATIN AMERICA: LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 116 GLOBAL PROSTATE CANCER INCIDENCE, 2022 VS. 2035 VS. 2050 152 TABLE 117 KEY LIQUID BIOPSY PRODUCTS FOR PROSTATE CANCER 152 TABLE 118 LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY REGION, 2023–2030 (USD MILLION) 152 TABLE 119 NORTH AMERICA: LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 120 EUROPE: LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 121 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 122 LATIN AMERICA: LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 123 GLOBAL MELANOMA INCIDENCE, 2022 VS. 2035 VS. 2050 155 TABLE 124 LIQUID BIOPSY MARKET FOR MELANOMA, BY REGION, 2023–2030 (USD MILLION) 155 TABLE 125 NORTH AMERICA: LIQUID BIOPSY MARKET FOR MELANOMA, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 126 EUROPE: LIQUID BIOPSY MARKET FOR MELANOMA, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 127 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR MELANOMA, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 128 LATIN AMERICA: LIQUID BIOPSY MARKET FOR MELANOMA, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 129 GLOBAL INCIDENCE OF OTHER CANCERS, 2022 VS. 2050 158 TABLE 130 LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY REGION, 2023–2030 (USD MILLION) 158 TABLE 131 NORTH AMERICA: LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY COUNTRY, 2023–2030 (USD MILLION) 158 TABLE 132 EUROPE: LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 133 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 134 LATIN AMERICA: LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY COUNTRY, 2023–2030 (USD MILLION) 160 TABLE 135 LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 161 TABLE 136 LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 161 TABLE 137 NORTH AMERICA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 161 TABLE 138 EUROPE: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 139 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 140 LATIN AMERICA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 141 KEY NIPT LIQUID BIOPSY PRODUCTS 164 TABLE 142 LIQUID BIOPSY MARKET FOR NIPT, BY REGION, 2023–2030 (USD MILLION) 164 TABLE 143 NORTH AMERICA: LIQUID BIOPSY MARKET FOR NIPT, BY COUNTRY, 2023–2030 (USD MILLION) 164 TABLE 144 EUROPE: LIQUID BIOPSY MARKET FOR NIPT, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 145 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR NIPT, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 146 LATIN AMERICA: LIQUID BIOPSY MARKET FOR NIPT, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 147 LIQUID BIOPSY MARKET FOR ORGAN TRANSPLANTATION, BY REGION, 2023–2030 (USD MILLION) 166 TABLE 148 NORTH AMERICA: LIQUID BIOPSY MARKET FOR ORGAN TRANSPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION) 167 TABLE 149 EUROPE: LIQUID BIOPSY MARKET FOR ORGAN TRANSPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION) 167 TABLE 150 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR ORGAN TRANSPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION) 167 TABLE 151 LATIN AMERICA: LIQUID BIOPSY MARKET FOR ORGAN TRANSPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION) 168 TABLE 152 LIQUID BIOPSY MARKET FOR INFECTIOUS DISEASE TESTING, BY REGION, 2023–2030 (USD MILLION) 169 TABLE 153 NORTH AMERICA: LIQUID BIOPSY MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2023–2030 (USD MILLION) 169 TABLE 154 EUROPE: LIQUID BIOPSY MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2023–2030 (USD MILLION) 169 TABLE 155 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2023–2030 (USD MILLION) 170 TABLE 156 LATIN AMERICA: LIQUID BIOPSY MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2023–2030 (USD MILLION) 170 TABLE 157 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 172 TABLE 158 LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY REGION, 2023–2030 (USD MILLION) 173 TABLE 159 NORTH AMERICA: LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY COUNTRY, 2023–2030 (USD MILLION) 174 TABLE 160 EUROPE: LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY COUNTRY, 2023–2030 (USD MILLION) 174 TABLE 161 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY COUNTRY, 2023–2030 (USD MILLION) 174 TABLE 162 LATIN AMERICA: LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY COUNTRY, 2023–2030 (USD MILLION) 175 TABLE 163 LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY REGION, 2023–2030 (USD MILLION) 176 TABLE 164 NORTH AMERICA: LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY COUNTRY, 2023–2030 (USD MILLION) 176 TABLE 165 EUROPE: LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY COUNTRY, 2023–2030 (USD MILLION) 176 TABLE 166 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY COUNTRY, 2023–2030 (USD MILLION) 177 TABLE 167 LATIN AMERICA: LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY COUNTRY, 2023–2030 (USD MILLION) 177 TABLE 168 LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY REGION, 2023–2030 (USD MILLION) 178 TABLE 169 NORTH AMERICA: LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 178 TABLE 170 EUROPE: LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 179 TABLE 171 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 179 TABLE 172 LATIN AMERICA: LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 180 TABLE 173 LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY REGION, 2023–2030 (USD MILLION) 181 TABLE 174 NORTH AMERICA: LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY COUNTRY, 2023–2030 (USD MILLION) 181 TABLE 175 EUROPE: LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY COUNTRY, 2023–2030 (USD MILLION) 181 TABLE 176 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY COUNTRY, 2023–2030 (USD MILLION) 182 TABLE 177 LATIN AMERICA: LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY COUNTRY, 2023–2030 (USD MILLION) 182 TABLE 178 LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 184 TABLE 179 LIQUID BIOPSY SAMPLES & APPLICATIONS 184 TABLE 180 KEY BLOOD SAMPLE-BASED PRODUCTS CURRENTLY AVAILABLE 186 TABLE 181 LIQUID BIOPSY MARKET FOR BLOOD SAMPLES, BY REGION, 2023–2030 (USD MILLION) 187 TABLE 182 NORTH AMERICA: LIQUID BIOPSY MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 187 TABLE 183 EUROPE: LIQUID BIOPSY MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 187 TABLE 184 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 188 TABLE 185 LATIN AMERICA: LIQUID BIOPSY MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 188 TABLE 186 LIQUID BIOPSY MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2023–2030 (USD MILLION) 189 TABLE 187 NORTH AMERICA: LIQUID BIOPSY MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION) 189 TABLE 188 EUROPE: LIQUID BIOPSY MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION) 190 TABLE 189 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION) 190 TABLE 190 LATIN AMERICA: LIQUID BIOPSY MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION) 190 TABLE 191 LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 192 TABLE 192 LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY REGION, 2023–2030 (USD MILLION) 193 TABLE 193 NORTH AMERICA: LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 194 TABLE 194 EUROPE: LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 194 TABLE 195 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 194 TABLE 196 LATIN AMERICA: LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 195 TABLE 197 LIQUID BIOPSY MARKET FOR HOSPITALS & PHYSICIANS LABORATORIES, BY REGION, 2023–2030 (USD MILLION) 196 TABLE 198 NORTH AMERICA: LIQUID BIOPSY MARKET FOR HOSPITALS & PHYSICIANS LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 196 TABLE 199 EUROPE: LIQUID BIOPSY MARKET FOR HOSPITALS & PHYSICIANS LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 197 TABLE 200 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR HOSPITALS & PHYSICIANS LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 197 TABLE 201 LATIN AMERICA: LIQUID BIOPSY MARKET FOR HOSPITALS & PHYSICIANS LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 198 TABLE 202 LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY REGION, 2023–2030 (USD MILLION) 199 TABLE 203 NORTH AMERICA: LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2023–2030 (USD MILLION) 199 TABLE 204 EUROPE: LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2023–2030 (USD MILLION) 200 TABLE 205 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2023–2030 (USD MILLION) 200 TABLE 206 LATIN AMERICA: LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2023–2030 (USD MILLION) 200 TABLE 207 LIQUID BIOPSY MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 201 TABLE 208 NORTH AMERICA: LIQUID BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 202 TABLE 209 EUROPE: LIQUID BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 202 TABLE 210 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 202 TABLE 211 LATIN AMERICA: LIQUID BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 203 TABLE 212 LIQUID BIOPSY MARKET, BY REGION, 2023–2030 (USD MILLION) 205 TABLE 213 NORTH AMERICA: NUMBER OF NEW CANCER CASES, BY CANCER TYPE, 2022 VS. 2050 206 TABLE 214 NORTH AMERICA: MACROECONOMIC INDICATORS 207 TABLE 215 NORTH AMERICA: LIQUID BIOPSY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 208 TABLE 216 NORTH AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 208 TABLE 217 NORTH AMERICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION) 208 TABLE 218 NORTH AMERICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 209 TABLE 219 NORTH AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 209 TABLE 220 NORTH AMERICA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 209 TABLE 221 NORTH AMERICA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 210 TABLE 222 NORTH AMERICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 210 TABLE 223 NORTH AMERICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 210 TABLE 224 NORTH AMERICA: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 211 TABLE 225 US: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 212 TABLE 226 US: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION) 212 TABLE 227 US: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 213 TABLE 228 US: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 213 TABLE 229 US: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 213 TABLE 230 US: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 214 TABLE 231 US: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 214 TABLE 232 US: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 214 TABLE 233 US: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 215 TABLE 234 US: TOTAL NUMBER OF WOMEN WHO UNDERGO NIPT TESTING, 2023–2030 (MILLION UNITS) 215 TABLE 235 CANADA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 216 TABLE 236 CANADA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION) 217 TABLE 237 CANADA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 217 TABLE 238 CANADA: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 217 TABLE 239 CANADA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 218 TABLE 240 CANADA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 218 TABLE 241 CANADA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 219 TABLE 242 CANADA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 219 TABLE 243 CANADA: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 219 TABLE 244 EUROPE: MACROECONOMIC INDICATORS 221 TABLE 245 EUROPE: LIQUID BIOPSY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 221 TABLE 246 EUROPE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 221 TABLE 247 EUROPE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION) 222 TABLE 248 EUROPE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 222 TABLE 249 EUROPE: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 222 TABLE 250 EUROPE: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 223 TABLE 251 EUROPE: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 223 TABLE 252 EUROPE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 224 TABLE 253 EUROPE: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 224 TABLE 254 EUROPE: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 224 TABLE 255 GERMANY: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 226 TABLE 256 GERMANY: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION) 226 TABLE 257 GERMANY: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 226 TABLE 258 GERMANY: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 227 TABLE 259 GERMANY: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 227 TABLE 260 GERMANY: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 227 TABLE 261 GERMANY: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 228 TABLE 262 GERMANY: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 228 TABLE 263 GERMANY: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 228 TABLE 264 UK: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 230 TABLE 265 UK: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION) 230 TABLE 266 UK: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 230 TABLE 267 UK: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 231 TABLE 268 UK: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 231 TABLE 269 UK: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 231 TABLE 270 UK: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 232 TABLE 271 UK: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 232 TABLE 272 UK: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 232 TABLE 273 FRANCE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 233 TABLE 274 FRANCE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION) 234 TABLE 275 FRANCE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 234 TABLE 276 FRANCE: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 234 TABLE 277 FRANCE: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 235 TABLE 278 FRANCE: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 235 TABLE 279 FRANCE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 236 TABLE 280 FRANCE: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 236 TABLE 281 FRANCE: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 236 TABLE 282 ITALY: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 237 TABLE 283 ITALY: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION) 238 TABLE 284 ITALY: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 238 TABLE 285 ITALY: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 238 TABLE 286 ITALY: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 239 TABLE 287 ITALY: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 239 TABLE 288 ITALY: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 240 TABLE 289 ITALY: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 240 TABLE 290 ITALY: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 240 TABLE 291 SPAIN: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 242 TABLE 292 SPAIN: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION) 242 TABLE 293 SPAIN: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 242 TABLE 294 SPAIN: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 243 TABLE 295 SPAIN: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 243 TABLE 296 SPAIN: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 243 TABLE 297 SPAIN: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 244 TABLE 298 SPAIN: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 244 TABLE 299 SPAIN: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 244 TABLE 300 REST OF EUROPE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 246 TABLE 301 REST OF EUROPE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION) 246 TABLE 302 REST OF EUROPE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 246 TABLE 303 REST OF EUROPE: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 247 TABLE 304 REST OF EUROPE: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 247 TABLE 305 REST OF EUROPE: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 247 TABLE 306 REST OF EUROPE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 248 TABLE 307 REST OF EUROPE: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 248 TABLE 308 REST OF EUROPE: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 248 TABLE 309 ASIA PACIFIC: MACROECONOMIC INDICATORS 250 TABLE 310 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 251 TABLE 311 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 251 TABLE 312 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION) 251 TABLE 313 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 252 TABLE 314 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 252 TABLE 315 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 252 TABLE 316 ASIA PACIFIC: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 253 TABLE 317 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 253 TABLE 318 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 253 TABLE 319 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 254 TABLE 320 CHINA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 255 TABLE 321 CHINA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION) 255 TABLE 322 CHINA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 256 TABLE 323 CHINA: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 256 TABLE 324 CHINA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 256 TABLE 325 CHINA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 257 TABLE 326 CHINA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 257 TABLE 327 CHINA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 257 TABLE 328 CHINA: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 258 TABLE 329 JAPAN: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 259 TABLE 330 JAPAN: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION) 259 TABLE 331 JAPAN: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 259 TABLE 332 JAPAN: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 260 TABLE 333 JAPAN: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 260 TABLE 334 JAPAN: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 260 TABLE 335 JAPAN: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 261 TABLE 336 JAPAN: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 261 TABLE 337 JAPAN: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 261 TABLE 338 INDIA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 263 TABLE 339 INDIA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION) 263 TABLE 340 INDIA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 263 TABLE 341 INDIA: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 264 TABLE 342 INDIA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 264 TABLE 343 INDIA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 264 TABLE 344 INDIA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 265 TABLE 345 INDIA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 265 TABLE 346 INDIA: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 265 TABLE 347 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 267 TABLE 348 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION) 267 TABLE 349 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 267 TABLE 350 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 268 TABLE 351 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 268 TABLE 352 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 268 TABLE 353 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 269 TABLE 354 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 269 TABLE 355 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 269 TABLE 356 LATIN AMERICA: MACROECONOMIC INDICATORS 271 TABLE 357 LATIN AMERICA: LIQUID BIOPSY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 271 TABLE 358 LATIN AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 272 TABLE 359 LATIN AMERICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION) 272 TABLE 360 LATIN AMERICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 272 TABLE 361 LATIN AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 273 TABLE 362 LATIN AMERICA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 273 TABLE 363 LATIN AMERICA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 273 TABLE 364 LATIN AMERICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 274 TABLE 365 LATIN AMERICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 274 TABLE 366 LATIN AMERICA: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 274 TABLE 367 BRAZIL: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 275 TABLE 368 BRAZIL: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION) 276 TABLE 369 BRAZIL: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 276 TABLE 370 BRAZIL: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 276 TABLE 371 BRAZIL: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 277 TABLE 372 BRAZIL: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 277 TABLE 373 BRAZIL: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 278 TABLE 374 BRAZIL: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 278 TABLE 375 BRAZIL: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 278 TABLE 376 MEXICO: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 279 TABLE 377 MEXICO: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION) 280 TABLE 378 MEXICO: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 280 TABLE 379 MEXICO: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 280 TABLE 380 MEXICO: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 281 TABLE 381 MEXICO: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 281 TABLE 382 MEXICO: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 282 TABLE 383 MEXICO: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 282 TABLE 384 MEXICO: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 282 TABLE 385 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 283 TABLE 386 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION) 284 TABLE 387 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 284 TABLE 388 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 284 TABLE 389 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 285 TABLE 390 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 285 TABLE 391 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 286 TABLE 392 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 286 TABLE 393 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 286 TABLE 394 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 288 TABLE 395 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 288 TABLE 396 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2023–2030 (USD MILLION) 289 TABLE 397 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 289 TABLE 398 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 289 TABLE 399 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 290 TABLE 400 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 290 TABLE 401 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 291 TABLE 402 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 291 TABLE 403 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY END USER, 2023–2030 (USD MILLION) 291 TABLE 404 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN LIQUID BIOPSY MARKET, JANUARY 2021−JUNE 2025 292 TABLE 405 LIQUID BIOPSY MARKET: DEGREE OF COMPETITION 295 TABLE 406 LIQUID BIOPSY MARKET: REGION FOOTPRINT 300 TABLE 407 LIQUID BIOPSY MARKET: PRODUCT & SERVICE FOOTPRINT 300 TABLE 408 LIQUID BIOPSY MARKET: APPLICATION FOOTPRINT 301 TABLE 409 LIQUID BIOPSY MARKET: DETAILED LIST OF KEY STARTUPS/SMES 303 TABLE 410 LIQUID BIOPSY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, BY PRODUCT & SERVICE 303 TABLE 411 LIQUID BIOPSY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, BY REGION 304 TABLE 412 LIQUID BIOPSY MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JUNE 2025 307 TABLE 413 LIQUID BIOPSY MARKET: DEALS, JANUARY 2021–JUNE 2025 308 TABLE 414 LIQUID BIOPSY MARKET: EXPANSIONS, JANUARY 2021–JUNE 2025 309 TABLE 415 NATERA, INC.: COMPANY OVERVIEW 311 TABLE 416 NATERA, INC.: PRODUCTS/SERVICES OFFERED 312 TABLE 417 NATERA, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021–JUNE 2025 313 TABLE 418 NATERA, INC.: DEALS, JANUARY 2021−JUNE 2025 314 TABLE 419 NATERA, INC.: OTHER DEVELOPMENTS, JANUARY 2021– JUNE 2025 314 TABLE 420 GUARDANT HEALTH: COMPANY OVERVIEW 316 TABLE 421 GUARDANT HEALTH: PRODUCTS/SERVICES OFFERED 317 TABLE 422 GUARDANT HEALTH: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021−JUNE 2025 318 TABLE 423 GUARDANT HEALTH: DEALS, JANUARY 2021−JUNE 2025 320 TABLE 424 MYRIAD GENETICS, INC.: COMPANY OVERVIEW 323 TABLE 425 MYRIAD GENETICS, INC.: PRODUCTS/SERVICES OFFERED 324 TABLE 426 MYRIAD GENETICS, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021−JUNE 2025 325 TABLE 427 MYRIAD GENETICS, INC.: DEALS, JANUARY 2021−JUNE 2025 325 TABLE 428 ILLUMINA, INC.: COMPANY OVERVIEW 329 TABLE 429 ILLUMINA, INC.: PRODUCTS/SERVICES OFFERED 330 TABLE 430 ILLUMINA, INC.:PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021−JUNE 2025 331 TABLE 431 ILLUMINA, INC.: DEALS, JANUARY 2021−JUNE 2025 332 TABLE 432 ILLUMINA, INC.: EXPANSIONS, JANUARY 2021−JUNE 2025 333 TABLE 433 ILLUMINA, INC.: OTHER DEVELOPMENTS, JANUARY 2021−JUNE 2025 334 TABLE 434 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 335 TABLE 435 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED 336 TABLE 436 F. HOFFMANN-LA ROCHE LTD.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021−JUNE 2025 337 TABLE 437 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2021−JUNE 2025 338 TABLE 438 QIAGEN N.V.: COMPANY OVERVIEW 339 TABLE 439 QIAGEN N.V.: PRODUCTS/SERVICES OFFERED 340 TABLE 440 QIAGEN N.V.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021−JUNE 2025 341 TABLE 441 QIAGEN N.V.: DEALS, JANUARY 2021−JUNE 2025 342 TABLE 442 QIAGEN: EXPANSIONS, JANUARY 2021−JUNE 2025 344 TABLE 443 EXACT SCIENCES CORPORATION: COMPANY OVERVIEW 345 TABLE 444 EXACT SCIENCES CORPORATION: PRODUCTS/SERVICES OFFERED 346 TABLE 445 EXACT SCIENCES CORPORATION: PRODUCT/SERVICE LAUNCHES, JANUARY 2021−JUNE 2025 347 TABLE 446 EXACT SCIENCES CORPORATION: DEALS, JANUARY 2021−JUNE 2025 347 TABLE 447 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 349 TABLE 448 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED 350 TABLE 449 THERMO FISHER SCIENTIFIC INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021−JUNE 2025 351 TABLE 450 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021−JUNE 2025 352 TABLE 451 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021−JUNE 2025 353 TABLE 452 GRAIL, INC.: COMPANY OVERVIEW 354 TABLE 453 GRAIL, INC.: PRODUCTS/SERVICES OFFERED 355 TABLE 454 GRAIL, INC.: PRODUCT/SERVICE APPROVALS, JANUARY 2021−JUNE 2025 355 TABLE 455 GRAIL, INC.: DEALS, JANUARY 2021−JUNE 2025 355 TABLE 456 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 357 TABLE 457 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED 359 TABLE 458 BIO-RAD LABORATORIES, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021−JUNE 2025 359 TABLE 459 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2021−JUNE 2025 360 TABLE 460 SYSMEX CORPORATION: COMPANY OVERVIEW 361 TABLE 461 SYSMEX CORPORATION: PRODUCTS/SERVICES OFFERED 362 TABLE 462 SYSMEX CORPORATION: DEALS, JANUARY 2021−JUNE 2025 363 TABLE 463 SYSMEX CORPORATION: EXPANSIONS, JANUARY 2021−JUNE 2025 364 TABLE 464 MDXHEALTH: COMPANY OVERVIEW 365 TABLE 465 MDXHEALTH: PRODUCTS/SERVICES OFFERED 366 TABLE 466 MDXHEALTH: DEALS, JANUARY 2021−JUNE 2025 366 TABLE 467 PERSONALIS, INC.: COMPANY OVERVIEW 367 TABLE 468 PERSONALIS, INC.: PRODUCTS/SERVICES OFFERED 368 TABLE 469 PERSONALIS, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021−JUNE 2025 369 TABLE 470 PERSONALIS, INC.: DEALS, JANUARY 2021−JUNE 2025 369 TABLE 471 THE MENARINI GROUP: COMPANY OVERVIEW 371 TABLE 472 THE MENARINI GROUP: PRODUCTS/SERVICES OFFERED 371 TABLE 473 THE MENARINI GROUP: PRODUCT/SERVICE LAUNCHES, JANUARY 2021−JUNE 2025 372 TABLE 474 THE MENARINI GROUP: DEALS, JANUARY 2021−JUNE 2025 372 TABLE 475 NEOGENOMICS LABORATORIES: COMPANY OVERVIEW 373 TABLE 476 ANGLE PLC: COMPANY OVERVIEW 374 TABLE 477 LABCORP HOLDINGS INC.: COMPANY OVERVIEW 375 TABLE 478 BIO-TECHNE: COMPANY OVERVIEW 376 TABLE 479 MESA LABS, INC.: COMPANY OVERVIEW 377 TABLE 480 MEDGENOME: COMPANY OVERVIEW 378 TABLE 481 LUNGLIFE AI, INC.: COMPANY OVERVIEW 379 TABLE 482 STRAND: COMPANY OVERVIEW 380 TABLE 483 VORTEX BIOTECH HOLDINGS: COMPANY OVERVIEW 381 TABLE 484 FREENOME HOLDINGS, INC.: COMPANY OVERVIEW 381 TABLE 485 LUCENCE HEALTH INC.: COMPANY OVERVIEW 382 TABLE 486 NEW DAY DIAGNOSTICS, LLC: COMPANY OVERVIEW 383 FIGURE 1 LIQUID BIOPSY MARKET SEGMENTATION & REGIONAL SCOPE 36 FIGURE 2 LIQUID BIOPSY MARKET: RESEARCH DESIGN METHODOLOGY 40 FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 45 FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 46 FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 47 FIGURE 6 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS 48 FIGURE 7 LIQUID BIOPSY MARKET: TOP-DOWN APPROACH 49 FIGURE 8 DATA TRIANGULATION METHODOLOGY 50 FIGURE 9 LIQUID BIOPSY MARKET: PARAMETRIC ASSUMPTIONS ANALYSIS 51 FIGURE 10 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION) 53 FIGURE 11 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER TYPE, 2025 VS. 2030 (USD MILLION) 54 FIGURE 12 LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION) 54 FIGURE 13 LIQUID BIOPSY MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 55 FIGURE 14 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2025 VS. 2030 (USD MILLION) 56 FIGURE 15 LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2025 VS. 2030 (USD MILLION) 57 FIGURE 16 LIQUID BIOPSY MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 57 FIGURE 17 LIQUID BIOPSY MARKET, BY REGION, 2025 VS. 2030 (USD MILLION) 58 FIGURE 18 INCREASING INCIDENCE OF CANCER AND ADVANCES IN LIQUID BIOPSY TECHNOLOGIES TO PROPEL MARKET 59 FIGURE 19 ASSAY KITS SEGMENT IS EXPECTED TO DOMINATE MARKET DURING FORECAST PERIOD 60 FIGURE 20 CIRCULATING TUMOR DNA SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 60 FIGURE 21 MULTI-GENE PARALLEL ANALYSIS USING NGS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 61 FIGURE 22 CANCER APPLICATIONS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 61 FIGURE 23 THERAPY SELECTION SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 62 FIGURE 24 BLOOD SAMPLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 62 FIGURE 25 REFERENCE LABORATORIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 63 FIGURE 26 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 63 FIGURE 27 LIQUID BIOPSY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 64 FIGURE 28 PATENT ANALYSIS FOR LIQUID BIOPSY (JANUARY 2015–DECEMBER 2024) 73 FIGURE 29 VALUE CHAIN ANALYSIS OF LIQUID BIOPSY MARKET: MAJOR VALUE-ADDED DURING MANUFACTURING & ASSEMBLY PHASES 76 FIGURE 30 LIQUID BIOPSY MARKET: SUPPLY CHAIN ANALYSIS 77 FIGURE 31 LIQUID BIOPSY MARKET: ECOSYSTEM ANALYSIS 80 FIGURE 32 LIQUID BIOPSY MARKET: PORTER’S FIVE FORCES ANALYSIS 81 FIGURE 33 LIQUID BIOPSY MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 91 FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR LIQUID BIOPSY PRODUCTS 92 FIGURE 35 KEY BUYING CRITERIA FOR LIQUID BIOPSY PRODUCTS 92 FIGURE 36 NUMBER OF DEALS & FUNDING ACTIVITIES IN LIQUID BIOPSY MARKET 93 FIGURE 37 MARKET POTENTIAL OF AI IN LIQUID BIOPSY MARKET 95 FIGURE 38 NORTH AMERICA: LIQUID BIOPSY MARKET SNAPSHOT 207 FIGURE 39 ASIA PACIFIC: LIQUID BIOPSY MARKET SNAPSHOT 250 FIGURE 40 REVENUE ANALYSIS OF LEADING FIVE PLAYERS, 2022−2024 294 FIGURE 41 MARKET SHARE ANALYSIS OF KEY PLAYERS (2024) 295 FIGURE 42 LIQUID BIOPSY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 298 FIGURE 43 LIQUID BIOPSY MARKET: COMPANY FOOTPRINT 299 FIGURE 44 LIQUID BIOPSY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 302 FIGURE 45 EV/EBITDA OF KEY VENDORS 305 FIGURE 46 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 305 FIGURE 47 BRAND COMPARISON: PCR-BASED LIQUID BIOPSY ASSAYS 306 FIGURE 48 NATERA, INC.: COMPANY SNAPSHOT (2024) 312 FIGURE 49 GUARDANT HEALTH: COMPANY SNAPSHOT (2024) 317 FIGURE 50 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2024) 324 FIGURE 51 ILLUMINA, INC.: COMPANY SNAPSHOT (2024) 330 FIGURE 52 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024) 336 FIGURE 53 QIAGEN N.V.: COMPANY SNAPSHOT (2024) 340 FIGURE 54 EXACT SCIENCES CORPORATION: COMPANY SNAPSHOT (2024) 346 FIGURE 55 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024) 350 FIGURE 56 GRAIL, INC.: COMPANY SNAPSHOT (2024) 354 FIGURE 57 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024) 358 FIGURE 58 SYSMEX CORPORATION: COMPANY SNAPSHOT (2024) 362 FIGURE 59 MDXHEALTH: COMPANY SNAPSHOT (2024) 365 FIGURE 60 PERSONALIS, INC.: COMPANY SNAPSHOT (2024) 368